CAMX•prnewswire•
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Summary
PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029),...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2026 by prnewswire